Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA finalises guides to improve reporting of safety information in drug trials

This article was originally published in SRA

Executive Summary

The US Food and Drug Administration has finalised two guidelines to help drug companies comply with its revised safety reporting requirements for investigational new drugs and bioavailability/bioequivalence studies that came into force in 20111-3.

You may also be interested in...



UK-US GCP Collaboration Going Strong But Mutual Recognition Not Feasible

While good clinical practice inspectors in the UK and the US collaborate on matters of common interest, they say that mutual recognition is simply not possible.

Hunt On For New Chair Of UK Regulator

Whoever takes over as chair of the Medicines and Healthcare products Regulatory Agency will play a key role in its plans to deliver a program of “ambitious business change.”

ICH Syncs Reproductive Toxicity Guidance With Current Science

The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.

UsernamePublicRestriction

Register

PS117103

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel